Interim report on CIV recombinant human endostatin in combination with docetaxel/cisplatin (DP)) in comparison to DP in the first-line treatment of phase IIIb/IV squamous-cell NSCLC (JSLCG-001): A multicenter, open-label, randomized phase III controlled study (NCT: 02513342).

Jian An Huang,Yong Song,Minhua Shi,Jian Feng,Xuedong Lv

Interim report on CIV recombinant human endostatin in combination with docetaxel/cisplatin (DP)) in comparison to DP in the first-line treatment of phase IIIb/IV squamous-cell NSCLC (JSLCG-001): A multicenter, open-label, randomized phase III controlled study (NCT: 02513342).

2019

Jian An Huang
Yong Song
Minhua Shi
Jian Feng
Xuedong Lv

e20541Background: Endostar registration Phase III and post-marketing Phase IV clinical study had confirmed Endostar in combination with Platinum double drugs can improve the NSCLC patients’ outcome...

Keywords:

Interim
Cell
Recombinant Human Endostatin
Pathology
Cisplatin
Oncology
Medicine
Docetaxel
Internal medicine
interim report
first line treatment
clinical study
open label

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations